The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy

Journal of Chemotherapy

Volumn 27, Issue 1, 2015, Pages 35-39

  Jiang, Ai Gui ^a   Lu, Hui Yu ^a  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

Author keywords

Advanced non small cell lung cancer; Cisplatin based chemotherapy; Glasgow prognostic score; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLASGOW PROGNOSTIC SCORE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SCORING SYSTEM; THORAX RADIOGRAPHY; TREATMENT RESPONSE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SERUM ALBUMIN; SURVIVAL ANALYSIS;

EID: 84920522821     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947814Y.0000000188     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
4. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on nonsmall cell lung cancer. J Thorac Oncol. 2011;6(4):824–33.
5. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227–30.
6. Ko YJ, Kwon YM, Kim KH, Choi HC, Chun SH, Yoon HJ, et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev. 2012;21(11): 2076–86.
7. Critselis E, Panagiotakos DB, Machairas A, Zampelas A, Critselis AN, Polychronopoulos E. Risk and predictive factors of hypoalbuminemia in cancer patients following extensive abdominal surgery despite total parenteral nutritional support. Int J Food Sci Nutr. 2012;63(2):208–15.
8. Sugimoto K, Komiyama H, Kojima Y, Goto M, Tomiki Y, Sakamoto K. Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg. 2012;29(6):503–9.
9. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;2(13):52.
10. Kubota T, Hiki N, Nunobe S, Kumagai K, Aikou S, Watanabe R, et al. Significance of the inflammation-based Glasgow prognostic score for short- and long-term outcomes after curative resection of gastric cancer. J Gastrointest Surg. 2012;16(11):2037–44.
11. Shimoda M, Katoh M, Kita J, Sawada T, Kubota K. TheGlasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy. 2010;56(6):501–6.
12. Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, et al. The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer. 2010;20(6):1052–7.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.
14. Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol. 2012; 7(4):655–62.
15. Kersten C, Louhimo J, Algars A, Lahdesmaki A, Cvancerova M, Stenstedt K, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol. 2013;52(8):1691–8.
16. Shimura T, Kitagawa M, Yamada T, Ebi M, Mizoshita T, Tanida S, et al. C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res. 2012;32(2):491–6.
17. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–4.
18. Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDonald N, Kasymjanova G, et al. Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer. 2010;102(7):1113–22.
19. Koch A, Fohlin H, Söenson S. Prognostic significance of Creactive protein and smoking in patients with advanced nonsmall cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol. 2009;4(3):326–32.
20. Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34(10):2393–8.
21. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, Serna- Thomé MG, Flores-Estrada D, Diaz-Romero C, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010;10:50.